Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 5/20 | 0.65 |
| ▸ | PTGS1 | P23219 | 4/20 | 0.65 |
| ▸ | SIRT1 | Q96EB6 | 2/20 | 0.65 |
| ▸ | EGLN1 | Q9GZT9 | 4/20 | 0.64 |
| ▸ | MEN1 | O00255 | 4/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.64 |
| ▸ | NPC1 | O15118 | 5/20 | 0.58 |
| ▸ | RAB9A | P51151 | 5/20 | 0.58 |
| ▸ | POLB | P06746 | 2/20 | 0.58 |
| ▸ | KDM4A | O75164 | 1/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.57 |
| ▸ | ATM | Q13315 | 1/20 | 0.57 |
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5227264 | 0.86 | MEN1 (0.59) | PTGS2PTGS1SIRT1MEN1KMT2A | |
| SCHEMBL28674794 | 0.85 | PTGS2 (0.75) | PTGS2PTGS1SIRT1MEN1KMT2A | |
| SCHEMBL8309972 | 0.84 | EGLN1 (0.71) | EGLN1MEN1KMT2ANPC1RAB9A | |
| SCHEMBL5231051 | 0.82 | PTGS2 (0.77) | PTGS2PTGS1SIRT1MEN1KMT2A | |
| SCHEMBL7951114 | 0.79 | EGLN1 (0.71) | EGLN1MEN1KMT2ANPC1RAB9A | |
| SCHEMBL7956952 | 0.79 | MEN1 (0.79) | EGLN1MEN1KMT2ANPC1RAB9A | |
| SCHEMBL28409319 | 0.79 | PTGS1 (1.00) | PTGS2PTGS1SIRT1MEN1KMT2A | |
| SCHEMBL8310038 | 0.79 | EGLN1 (1.00) | EGLN1MEN1KMT2ANPC1RAB9A | |
| SCHEMBL28641186 | 0.78 | PTGS1 (0.67) | PTGS2PTGS1SIRT1MEN1KMT2A | |
| SCHEMBL9276493 | 0.78 | MEN1 (1.00) | PTGS2PTGS1SIRT1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1326611-B1 | AZA- AND POLYAZA-NAPHTHALENYL-CARBOXAMIDES USEFUL AS HIV INTEGRASE INHIBITORS | MERCK & CO INC (US) | 2007-06-13 | — | — | EP | claimed |
| EP-1326611-A4 | AZA- AND POLYAZA-NAPHTHALENYL-CARBOXAMIDES USEFUL AS HIV INTEGRASE INHIBITORS | MERCK & CO INC (US) | 2004-04-07 | — | — | EP | claimed |
| US-20040034221-A1 | Aza-and polyaza-naphthalenyl-carboxamides useful as hiv integrase inhibitors | MERCK SHARP & DOHME CORP. | 2004-02-19 | — | — | US | claimed |
| EP-1326611-A1 | AZA- AND POLYAZA-NAPHTHALENYL-CARBOXAMIDES USEFUL AS HIV INTEGRASE INHIBITORS | Merck & Co., Inc. (US) | 2003-07-16 | — | — | EP | claimed |
| US-6500842-B1 | N-((4-CHLOROPHENYL)METHYL)-8-HYDROXY-7-QUINOLINECARBOXAMIDE ADMINISTERED AS VIRICIDES AGAINST HERPES VIRUS | PHARMACIA & UPJOHN COMPANY | 2002-12-31 | — | — | US | claimed |
| WO-2002030426-A1 | AZA- AND POLYAZA-NAPHTHALENYL-CARBOXAMIDES USEFUL AS HIV INTEGRASE INHIBITORS | MERCK & CO., INC. (US) | 2002-04-18 | — | — | WO | claimed |
| EP-0927164-A1 | 8-HYDROXY-7-SUBSTITUTED QUINOLINES AS ANTI-VIRAL AGENTS | PHARMACIA & UPJOHN COMPANY (US) | 1999-07-07 | — | — | EP | claimed |
| WO-1998011073-A1 | 8-HYDROXY-7-SUBSTITUTED QUINOLINES AS ANTI-VIRAL AGENTS | PHARMACIA & UPJOHN COMPANY (US) | 1998-03-19 | — | — | WO | claimed |
| EP-1326611-B1 | AZA- AND POLYAZA-NAPHTHALENYL-CARBOXAMIDES USEFUL AS HIV INTEGRASE INHIBITORS | MERCK & CO INC (US) | 2007-06-13 | — | — | EP | disclosed |
| EP-1326611-B1 | AZA- AND POLYAZA-NAPHTHALENYL-CARBOXAMIDES USEFUL AS HIV INTEGRASE INHIBITORS | MERCK & CO INC (US) | 2007-06-13 | — | — | EP | disclosed |
| US-6919351-B2 | Aza-and polyaza-naphthalenyl-carboxamides useful as HIV integrase inhibitors | MERCK & CO., INC. (US) | 2005-07-19 | — | — | US | disclosed |
| EP-1326611-A4 | AZA- AND POLYAZA-NAPHTHALENYL-CARBOXAMIDES USEFUL AS HIV INTEGRASE INHIBITORS | MERCK & CO INC (US) | 2004-04-07 | — | — | EP | disclosed |
| US-20040034221-A1 | Aza-and polyaza-naphthalenyl-carboxamides useful as hiv integrase inhibitors | MERCK SHARP & DOHME CORP. | 2004-02-19 | — | — | US | disclosed |
| EP-1326611-A1 | AZA- AND POLYAZA-NAPHTHALENYL-CARBOXAMIDES USEFUL AS HIV INTEGRASE INHIBITORS | Merck & Co., Inc. (US) | 2003-07-16 | — | — | EP | disclosed |
| WO-2002030426-A1 | AZA- AND POLYAZA-NAPHTHALENYL-CARBOXAMIDES USEFUL AS HIV INTEGRASE INHIBITORS | MERCK & CO., INC. (US) | 2002-04-18 | — | — | WO | disclosed |
| US-6310211-B1 | ANTI-VIRAL ACTIVITY AGAINST HERPES VIRUS, CYTOMEGALOVIRUS. MANY OF THESE COMPOUNDS ARE ALSO ACTIVE AGAINST VARICELLA ZOSTER VIRUS, EPSTEIN-BARR VIRUS, HERPES SIMPLEX VIRUS AND HUMAN HERPES VIRUS TYPE 8 | PHARMACIA & UPJOHN COMPANY | 2001-10-30 | — | — | US | disclosed |
| US-6252080-B1 | HERPES, CYTOMEGALO VIRUS | PHARMACIA & UPJOHN COMPANY | 2001-06-26 | — | — | US | disclosed |
| US-6211376-B1 | HERPES VIRUS, CYTOMEGALO VIRUS, VARICELLA-ZOSTER VIRUS,EPSTEIN-BARR VIRUS | PHARMACIA & UPJOHN COMPANY | 2001-04-03 | — | — | US | disclosed |
| EP-0927164-A1 | 8-HYDROXY-7-SUBSTITUTED QUINOLINES AS ANTI-VIRAL AGENTS | PHARMACIA & UPJOHN COMPANY (US) | 1999-07-07 | — | — | EP | disclosed |
| WO-1998011073-A1 | 8-HYDROXY-7-SUBSTITUTED QUINOLINES AS ANTI-VIRAL AGENTS | PHARMACIA & UPJOHN COMPANY (US) | 1998-03-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040034221-A1 | Aza-and polyaza-naphthalenyl-carboxamides useful as hiv integrase inhibitors | POLI, DUT, NAAA | PTGS2 2974/4885PTGS1 2931/4885SIRT1 328/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.